COMMUNIQUÉS West-GlobeNewswire

AMSilk collaboration: Biotech silk protein yarns feature in Balenciaga 55th Couture Collection
04/08/2026
Haute Couture evening gown constructed using AMSilk-blend fabric Follows debut of AMSilk bioengineered silk protein yarns in Balenciaga Spring Collection 2026 NEURIED, Germany, Aug. 04, 2026 (GLOBE NEWSWIRE) -- AMSilk, [...]
Transactions in connection with share buy-back program
04/08/2026
Company announcement no. 28 - 26 04 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
04/08/2026
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
04/08/2026
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP by joint consensus [...]
Communiqué de presse : MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques
04/08/2026
MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques Paris, le 4 août 2026. Sanofi a annoncé aujourd’hui que la [...]
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
04/08/2026
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an [...]
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
04/08/2026
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor BRISBANE, Calif., Aug. 04, 2026 (GLOBE [...]
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
04/08/2026
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46 th Annual Growth Conference in Boston on August 12-13 [...]
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
04/08/2026
BEIJING, Aug. 03, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that orelabrutinib [...]
Rapid Nutrition Joins Global Conversation on the Future of AI-Driven HealthTech
04/08/2026
Growing recognition across leading international business media highlights increasing interest in the convergence of artificial intelligence, personalized wellness and digital health. LONDON, Aug. 03, 2026 (GLOBE [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
04/08/2026
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
REACT19 Launches $100,000 Matching Campaign as Demand for Medical Grants Surges 33%
03/08/2026
Six families need help today. Fifteen more are already waiting. Every donation through September will be doubled to provide life-saving medical care MEQUON, Wisc., Aug. 03, 2026 (GLOBE NEWSWIRE) -- REACT19 today [...]
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
03/08/2026
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company [...]
HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule
03/08/2026
DRAPER, Utah, Aug. 03, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]
Keros Therapeutics Reports Second Quarter 2026 Financial Results
03/08/2026
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
03/08/2026
August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune [...]
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it [...]
Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
03/08/2026
Generated second quarter revenue of $200.6 million Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14 Second quarter operating cash flow of $23.2 million Announced strategic growth plan designed to [...]

Pages